A solid tumor that has not responded to previous treatment.
Age must be 6 months or older to younger than 18 years of age.
Disease must be measurable by accepted tests.
Availability of tumor tissue at study enrollment is mandatory.
Prior treatment with cobimetinib or other similar drug.
Treatment with high-dose chemotherapy and stem-cell rescue within 3 months prior to the study.

A diagnosis of leukemia, specifically de novo high B-ALL with eligible genetic changes.
Age must be greater than 1 year old and less than or equal to 21 years old at leukemia diagnosis.
Have completed an acceptable induction therapy either on study or by hospital standard of care.
Had any other chemotherapy before induction therapy, with exceptions.
Down Syndrome.

A diagnosis of acute GVHD.
2 months of age and older to under 18 years of age.
Patient has failed to respond to steroid treatment.
Has had any second line therapy to treat aGVHD.
Severe hepatic veno-occlusive disease (VOD).

Age 6 to 21 Inclusive
Cancer that has returned or is not responding to previous therapy
Has failed at least one prior therapy
Certain prior therapies

Stage 1-3 breast cancer
Scheduled to start neoadjuvant chemotherapy
Sedentary
No heart disease
Stage 4 breast cancer
Heart disease
Non-English speaking

A diagnosis of pediatric cancer of varying types for which there is no known cure or disease that is not responding to treatment.
Must be over one year of age at enrollment.
Must be less than or equal to 21 years at initial diagnosis.
Must have measurable disease by accepted standards.
Tumor must be accessible for biopsy.
Has received chemotherapy within the last 7 days of biopsy.
Has received any radiotherapy to the primary sample site within the last 14 days.
Currently taking any other study drug.

At least 18 years of age
Received a cancer diagnosis previously
Lives in central Pennsylvania
Below the age of 18
No history of cancer
Lives outside of the Penn State Cancer Institute's 28-county catchment area

Ages 0-21 years at the time of diagnosis.
Diagnosis of neuroblastoma or medulloblastoma.
Disease has not responded to previous treatment.
Disease is measurable bu accepted tests.
Patients who weigh less than 3.5 kg (7.7 lbs).
Currently receiving another study drug.
Currently receiving other anticancer agents.

A confirmed diagnosis of neuroblastoma.
Must be in complete remission (CR).
Tests and scans will be required to confirm remission.
Patients below the defined minimum of height and weight.
Patients who are currently receiving another study drug may not participate.
Patients who are currently receiving other anticancer agents may not participate.

Diagnosis of relapsed or refractory leukemia or solid timor.
Age 6 months to less than 30 years at enrollment.
Must be fully recovered from effects of previous treatment.
Life expectancy greater than or equal to 3 months.
Prior treatment with carfilzomib.
Known allergy to Captisol®.
Down syndrome.

metastatic breast cancer
ECOG<3
English speaking
sufficient vision/hearing or family support
Medical or psychiatric conditions (beyond breast cancer, its treatment, and its symptoms) that would impair our ability to test study hypotheses (e. g. psychotic disorders, dementia, inability to give informed consent or follow the instruction).
Patients who are receiving any other behavioral intervention

New diagnosis of leukemia (de novo ALL) or lymphoma (T or B cell).
An acceptable planned induction chemotherapy.
One year of age and older to less than 18 years of age.
Able to take oral medication or have it given through a tube.
Had a blood clot in the past 3 months.
Known inherited bleeding disorder.

Must be older than 1 month of age.
Scheduled for a stem cell transplant and be at high risk of veno-occlusive disease.
Be at high risk of veno-occlusive disease.
Unstable blood pressure.
Episodes of bleeding.

Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment
Subjects must be =< 25 years of age at time of original diagnosis
Enrollment can occur at any time after disease presentation
All patients or their parents or legally authorized representatives must sign a written informed consent
Age >= 25 years

At least one (1) measurable and biopsy-confirmed papillary Low Grade tumor, evaluated visually, ≤ 15 mm.
ECOG (Eastern Cooperative Oncology Group) performance status <3 (with Karnofsky >40).
Life expectancy greater than 24 months.
Adequate organ and bone marrow function as determined by routine laboratory tests
New or recurrent patients with LG, non-invasive UTUC in the pyelocalyceal system.
Patient received BCG treatment for UC during the 6 months prior to Visit 1.
The patient has untreated concurrent urothelial cancer in other locations other than the target area (unless treated during screening).
Carcinoma in situ (CIS) in the past in the urinary tract.
Patient has a history of invasive urothelial carcinoma in the urinary tract during the past 5 (Five) years.
Patient is actively being treated or intends to be treated with systemic chemotherapy during the duration of the trial.

Patients must have B-ALL with ≥ 5% (M2 or M3) bone marrow blasts with or without extramedullary disease
Leukemic blasts must demonstrate surface expression of CD22 at the time of relapse by local/institutional flow cytometry of a bone marrow aspirate sample.
Second or greater relapse; Primary refractory disease with at least 2 prior induction attempts
First relapse refractory to at least one prior re-induction attempt
Patients with Ph+ ALL must have had two prior therapy attempts including two different tyrosine kinase inhibitors (TKIs).
Patients with any prior history of SOS/VOD irrespective of severity
Patients with isolated CNS, testicular, or other extramedullary site of relapse
Patients who have been previously treated with InO
History of allergic reaction attributed to compounds of similar or biologic composition to InO or other agents in the study.
Patients with active optic nerve and/or retinal involvement that would require urgent radiation therapy concurrent with protocol therapy

Be ≥1 year and <75 years of age
A diagnosis of acute leukemia in remission
Prior transplant
Acute bleeding

Stage IV locally advanced node positive or metatatic-M1 positive urothelial cancer of bladder and upper tract
Histologically proven urothelial cancer of bladder with prdominant transitional cell component
Presence of measurable disease per RECIST v1.1 for solid tumors
Patients who are cisplatin ineligible as defined in the protocol
patients must be treatment naive for metastatic disease.
Previous treatment with PD1 or PD-L1 inhibitor, including Avelumab
Previous systemic immunotherapy
History of another primary malignancy (except for malignancy treated with curative inten & no known active disease for greater than 5 years, adequately treated non-melanoma skin cancer, lentigo maligna or carcinoma insitu without evidence of disease
Current or prior use of immunosuppressive medication within 28 days before registration
Clinically significant cardiovascular disease

Adult >20 years of age
Newly diagnosed with any stage or type of cancer within 3 months OR progression of disease within 3 months of enrollment. Recurrence of cancer within 3 months of enrollment would also be eligible as it will be considered as progression of cancer
Ability to understand English language and ability to write without any functional difficulty
ECOG performance status 0-3
Inability to give informed consent
Severe psychiatry illness (e.g., uncontrolled depression, schizophrenia or psychosis
Severe cognitive impairment
Pregnant females
Inability to write or understand English

Female
Age: between 40 and 74 years of age
Had a screening mammogram with the following findings: negative or benign, heterogeneously dense or extremely dense breasts
History of breast cancer

Scheduled for colonoscopy in the next 4 months
age 50 and older who are undergoing their first ever screening colonoscopy
adults age 70 and older with colonoscopy more than 9.5 years ago
willing to provide blood, urine and stool samples
able to tolerate removal of 5 tubes (3.5 tablespoons) of blood
positive stool blood test (FIT/FOBT) in the past year
ever had colon or rectal cancer
history of inflammatory bowel disease
confirmed hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, HIV or chronic viral hepatitis
cancer diagnosis or treatment in past year

Female, age of 18 years or older
Cytology confirmed primary invasive breast cancer, ductal carcinoma in situ or a combination of both
Scheduled for lumpectomy for a breast malignancy
No uncontrolled serious medical problems
Subjects who are pregnant at the time of breast cancer diagnosis
Uncontrolled hypertension or other uncontrolled medical problems
Patient who is sexually active and not willing to use contraception-hormonal or barrier method, or abstinence for 60 days after injection
Individuals undergoing a second lumpectomy because of previous positive margins
Subjects who have taken an investigational drug in the 30 days prior to enrollement

Adult (45-70)
Colorectal cancer diagnosis stage 1 through 3
Completed primary cancer treatment at least 3 months prior to participating
Have a scheduled colonoscopy or plan to schedule in the next 90 days
Fluent in English
No colorectal cancer diagnosis, or diagnosis of Stage 0 or 4 colorectal cancer
Under the age of 45 or over the age of 70
Diagnosis of psychiatric disorder AND recent hospitalization
Visual impairments that would prevent use of mobile device or computer use
Severe cognitive impairment

A confirmed diagnosis of neuroblastoma.
Must be 21 years of age or younger when diagnosed.
No prior systemic therapy with some exceptions.
Tumor samples will be obtained only in a non-significant risk manner and not solely for the purpose of the study.
Receiving another study drug while on this study.
Female patients who are lactating are not eligible unless they agree not toe breast feed.

Subjects with histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
Subjects without EGFR activating mutation nor ALK translocation.
Subjects who progressed after first-line platinum-based chemotherapy and who are candidates for second-line therapy.
Subjects with stage IV non-small cell lung cancer (NSCLC) as defined by American Joint Committee on Cancer (AJCC).
Measurable disease according to RECIST v1.1 (Section 8) obtained by imaging within 28 days prior to study registration.
Surgery within 4 weeks prior to study registration except for minor procedures.
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis.
Previously received an organ or allogeneic progenitor/stem cell transplant.
Received a live vaccine within 30 days prior to the first dose of trial treatment. Examples of live vaccines include, but are not limited to: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine.
History of blood clots, pulmonary embolism, or deep vein thrombosis unless on adequate anticoagulant therapy as determined by the treating investigator (subject must be on stable dose for 2 weeks).

65 years or older
Willing to participate in focus group discussion
Diagnosed with non-skin cancer within the past 5 years

Cancer pateint or survivor who receive care for an HPV-related cancer at the Penn State Cancer Institute
Speak English
18 years or older
Male or female
Minors

Newly Diagnosed higher risk RCC of any histology
No clinical or radiological evidence of distant metastases
No concurrent or prior systemic or local anti-cancer therapy for RCC is permitted
Age must be greater than or equal to 18 years old
ECOG Performance status must be 0 or 1
Women must not be pregant or breast feeding
History of RCC that was resected with curative intent within the past 5 years
Prior or current prostate cancer is excluded
Active known or suspected autoimmune disease
Uncontrolled adrenal insufficiency

Confirmed solid tumor of varying types which has not responded to previous treatment.
Age at beginning of study is less than 30 years.
Weighs at least 3 kilograms (6.6 pounds).
Disease that is measurable based on accepted standards.
Tumor tissue from past surgery is available or willingness to have a biopsy prior to enrollment.
Known brain tumor.
Patients with lymphoma, or other related diseases.
Treatment with high-dose chemotherapy and hematopoietic stem-cell rescue within a certain period of starting the study drug.
Prior stem-cell transplantation or prior solid-organ transplant.

Age 18-80
MRI documenting primary brain tumor with presumed malignant glioma
Intended surgical resection
Karnofsky >= 60%
Radiographic tumors of, or involving, nonresectable midline, basal ganglia or brainstem
Personal or family history of porphyria
Women who are pregnant